Literature DB >> 15219368

[Angioedema and angiotensin converting enzyme inhibitors: a report of 19 cases].

J-P Ducroix1, S Outurquin, B Benabes-Jezraoui, V Gras, G Chaby, V Strunski, V Salle, A Smail, C Lok, M Andrejak.   

Abstract

PURPOSE: Inhibitors of angiotensin-converting enzyme are worldwide used and are a real progress for the treatment of systemic hypertension or cardiac failure and are a real progress. The most common adverse side effect is cough. Angioedema is a sudden and localized edema involving the deeper cutaneous and mucosa tissue lappers. 0.1-0.5% of patients treated by ACE inhibitors could develop angioedema.
MATERIALS AND METHODS: We report a series of 19 cases, recruited in the Parmacovigilance Center of the University Hospital of Amiens from 1997 to 2003.
RESULTS: All the patients had a facial swelling edema at initial presentation. Intestinal mucosa or preputial are misleading localisations. In 1/3 of cases, angioedema appeared after the first administration, in 1/3 of cases it appeared with a delay of 1-2 years. The oropharynx localisation with glottic involvement may need an airway intervention. One patient died from pulmonary distress at home.
CONCLUSION: The pathophysiology is current unknown although there is increasing evidence for bradykinin accumulation involvement. The treatment by ACE inhibitors must be broken off; angiotensin II antagonists may be an alternative treatment, but has to be introduced carefully.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15219368     DOI: 10.1016/j.revmed.2004.02.024

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  2 in total

Review 1.  Drug-induced urticarias.

Authors:  Pascale Mathelier-Fusade
Journal:  Clin Rev Allergy Immunol       Date:  2006-02       Impact factor: 8.667

2.  Association of B2 receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans.

Authors:  Retsilisitsoe R Moholisa; Brian R Rayner; E Patricia Owen; Sylva L U Schwager; Joalice S Stark; Motassim Badri; Clint L Cupido; Edward D Sturrock
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-11       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.